Top Medical News
Why do psoriasis patients report better QoL amid COVID-19?
8 hours ago
Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.
Deucravacitinib bests placebo, apremilast in moderate-to-severe plaque psoriasis
3 days ago
Treatment with deucravacitinib achieves better efficacy than placebo and apremilast in patients with moderate-to-severe plaque psoriasis, while also yielding a good safety profile, reports a recent study.
Ruxolitinib cream achieves durable itch-free state in atopic dermatitis
4 days ago
Among adults and adolescents with atopic dermatitis (AD), ruxolitinib cream helps sustainably improve itching, reports a recent analysis.
Eczema in kids: Ciclosporin induces rapid response, methotrexate affords sustained disease control
27 Sep 2022
In the treatment of children with atopic eczema, ciclosporin is linked to a more rapid response while methotrexate (MTX) is associated with sustained disease control following discontinuation, a study has found.
Pembrolizumab extends RFS in stage II melanoma
25 Sep 2022
In acral melanoma (AM) patients with Breslow thickness >2 mm, tumour thickness does not appear to affect survival, a recent study has found.
Psoriasis cream scores high in DERMIS trials
Jairia Dela Cruz, 23 Sep 2022
Applying roflumilast cream topically once-a-day helps clear plaque psoriasis in 8 weeks, according to pooled data from the phase III DERMIS-1 and DERMIS-2 trials.
Rocatinlimab a new treatment option for head and neck AD?
Audrey Abella, 23 Sep 2022
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
Special Reports
Product Highlight - Canespro
15 Jun 2022
Bifonazole Anti-Fungal Cream 1% w/w
Product Highlight - RELIZEMA
16 Jun 2021
Furfuryl Palmitate
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Cochrane review confirms Atopiclair efficacy in eczema
22 Dec 2017
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]
Conference Reports
Rocatinlimab a new treatment option for head and neck AD?
Audrey Abella, 23 Sep 2022
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata
Audrey Abella, 21 Sep 2022
In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).
Roflumilast shows treatment potential for seborrheic dermatitis
Audrey Abella, 15 Sep 2022
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
Baricitinib may improve hair regrowth in alopecia areata
Roshini Claire Anthony, 02 May 2022

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.

Dupilumab stops the itch, clears skin lesions in phase III trial
Elvira Manzano, 29 Apr 2022
The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.
Roflumilast cream reduces psoriasis severity
Elaine Soliven, 27 Apr 2022
Using a topical roflumilast cream to treat patients with chronic plaque psoriasis yields a significant improvement in disease severity, achieving a clear or almost clear IGA* status, based on a pooled analysis of the DERMIS-1** and DERMIS-2*** studies presented at AAD 2022.
Cutaneous reactions after 1st COVID-19 vaccine dose no reason to forgo 2nd dose
Elvira Manzano, 27 Apr 2022
Skin reactions to the first COVID-19 vaccine in some individuals shouldn’t be a reason to leave out the second dose, or a scheduled booster if tolerable, according to an analysis presented at AAD 2022.
Product Highlights
CME Modules